Zacks Small Cap Research on MSN
MTVA: Positive results for 48 mg cohort in phase 1b trial of DA-1726
By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Results for 8-week 48 mg Cohort ...
Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
Niigata, Japan - A new Japanese study reveals significant birth cohort effects on the incidence trend of ESKD requiring RRT. “Different birth cohorts may have different levels of exposure to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback